pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›adebrelimab
drug
save

adebrelimab

updated 3mo ago
by Jiangsu Hengrui Pharmaceuticals Co Ltd
community read0 votes

🐶 often sniffed alongside

top 6
  • tagOncology6 co-mentions · 3 sources
  • tagNSCLC3 co-mentions · 2 sources
  • tagPulmonology2 co-mentions · 2 sources
  • companyJiangsu Hengrui Pharmaceuticals Co Ltd1 co-mentions · 1 sources
  • companyHospital Of Dalian Medical University 11 co-mentions · 1 sources
  • companyNanfang Hospital of Southern Medical University1 co-mentions · 1 sources

all catalysts(3)

phase 1 2 completion · 1
Apr 30, 2026
phase 1 2 completion
4mo ago
Jiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)
adebrelimab
→
phase 2 completion · 2
Apr 30, 2026
phase 2 completion
4mo ago
Hospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)
adebrelimab
→
Apr 30, 2026
phase 2 completion
4mo ago
Nanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)
adebrelimab
→

Trials studying adebrelimab

  • phase2Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancerrecruitingn=43
  • phase3A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinomanot yet recruitingn=690
  • phase2A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinomanot yet recruitingn=120
  • phase2A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumorsrecruitingn=156
  • phase2Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAICnot yet recruitingn=38
  • phase3Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancernot yet recruitingn=874
  • phase2Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLCwithdrawn
  • phase2A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancerrecruitingn=200
more trials →

News(1)

  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 3mo ago
Data sources
ClinicalTrials.gov
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?